Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden
Authors:
- Jianguang JiJJJianguang Ji
- Kristina SundquistKSKristina Sundquist
- Jan SundquistJSJan Sundquist
- 1 June 2012
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (6) , 642-648
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Update on degenerative ataxiasCurrent Opinion in Neurology, 2011
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- p53 and its mutants in tumor cell migration and invasionJournal of Cell Biology, 2011
- Cancer and Neurodegeneration: Between the Devil and the Deep Blue SeaPLOS Genetics, 2010
- Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyondThe Lancet Neurology, 2010
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?Nature Reviews Cancer, 2009
- Huntington disease as a dual diagnosis disorder: Data from the national research roster for Huntington disease patients and familiesDrug and Alcohol Dependence, 2007
- Polyglutamine PathogenesisNeuron, 2002
- Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's diseaseNature Genetics, 1993